Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvakitug in Moderately to Severely Active Crohn's Disease
NCT07184944Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Jan 2026
- Primary completion
- Aug 2029
- Modality
- Monoclonal Antibodies
- Countries
- 27
01
Overview
A Phase 3 trial of duvakitug in Crohn's disease, sponsored by Sanofi. Started Jan 2026; status: recruiting.
02
Drugs
duvakitug
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT07184944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07184944.